Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2022 Earnings Presentation
23 slides from Lincoln Pharmaceuticals's earnings presentation, 2021
Slide 1: Q1 FY2022 Earnings Presentation
Q1 FY2022 Earnings Presentation GROWING IS COMMITMENT. WE POSSESS. P H A R M A C E U T IC A L S LT D . H E ALTH C A R E F O R A L L www.lincolnpharma.com 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfo
Slide 3: Corporate Overview
CORPORATE OVERVIEW BACKGROUND PRODUCT PORTFOLIO MANUFACTURING EXPORTS • Established in the year 1979, • 1700 registered products and • Manufacturing facility at • Exports increased to 65% of in Lincoln Pharma has developed another 700 in pipeline Khatraj in Ahmedabad, Gujarat FY21 from 11% in FY13.
Slide 4: Q1 FY22 Business Performance & Roadmap
Q1 FY22 Business Performance & Roadmap • Company is confident to improve revenue, margins and profitability in FY22. Strategic growth initiatives, product and geographical expansion, operational efficiency and debt free status are likely to maximise value for all stakeholders in the near to medium t
Slide 5: Q1FY22 Consolidated Results
Q1FY22 Consolidated Results NET REVENUE EBITDA PAT 17.7 27.3 124.2 17.6% 14.0% 16.0% 24 15.3 105.6 Q1FY21 Q1FY22 Q1FY21 Q1FY22 Q1FY21 Q1FY22 Q1 FY2022 Earnings Presentation Fig (Rs. Cr) 5
Slide 6: Performance – Focused Therapeutic Areas and Geography
Performance – Focused Therapeutic Areas Revenue Breakup 4% 2% 3% 2% General Anti Infectives 26.20% 9% 24% 31.80% Therapeutic Area Respiratory Systems 29.20% 26.80% 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones Q1 FY22 Q1 FY21 13% 15% Musculo-Skeletal System 10.30% 14% 7.
Slide 7: Performance Overview
Performance Overview Consolidated Financial Performance (Rs. Cr) Q1 Y-o-Y Q4 Q-o-Q Full Year Y-o-Y Growth Growth Growth Particulars FY2022 FY2021 FY2021 FY2021 FY2020 (%) (%) (%) Net Revenue 124.2 105.6 17.6% 82.1 51.2% 429.9 397.5 8.1% EBITDA 27.3 24.0 14.0% 17.8 53.7% 92.8 76.6 21.1% Margin (%) 22
Slide 8: About - Lincoln Pharmaceuticals Ltd
About - Lincoln Pharmaceuticals Ltd Providing Affordable and Innovative medicines for healthier lives. VISION To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging Strategic alliances both domestically and internationally. MISSION • Focused on deliver
Slide 9: Key Milestones
Key Milestones 1979 1984-85 1995 1996-97 Lincoln was incorporated & Received WHO – GMP for plant / Converted in to a Public Limited commences operations as a Launched IPO & Listed on BSE production unit Company Partnership Firm 2015-16 2016-17 2000 2010-11 Listed on NSE Launched 3 products which are
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap • Pollution Control Board granted permission for setting up API Unit CAPEX • Civil Work for the Cephalosporin Plant is going on and it will complete soon. Total Capex estimated is Rs.40-45 crore. • Export Network to increase to 90+ Countries from 60 curre
Slide 11: Lincoln Pharmaceuticals Ltd - Financial Overview
Lincoln Pharmaceuticals Ltd - Financial Overview Year Revenue EBITDA PAT EPS Share Price FY 21 424 92 62 31.11 225 FY 11 189 13 6 4.51 35 10 Yrs CAGR 8.42% 21.61% 26.31% 21.33% 20.45% Book Value (Per Share) Market Cap (Rs. Cr) Net Debt (Rs. Cr) 472 188 450 420 425 157 108 108 135 71.1 112 268 96 -7.
Slide 12: Business Revenue Mix
Business Revenue Mix Particular (Rs. cr) FY 2013 (%) FY 2017 (%) FY 2021 (%) Domestic Sales 145.03 74.5% 246.46 67.4% 154.63 36.5% Exports 49.67 25.5% 119.27 32.6% 269.56 63.5% FY13 FY17 FY21 25.5% 32.6% 36.5% 63.5% 67.4% 74.5% Exports Domestic Exports Domestic Exports Domestic Q1 FY2022 Earnings Pr
Slide 13: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Africa: Angola, Benin, Botswana, Asia : Afghanistan, Armenia, America : Bolivia, Burkina Faso, Burundi, Cameroon, Azerbaijan, Bhutan
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced as First Time in India Anti-fungal vaginal spray Diclofenac rectal spray Sildenafil oral spray Ondansetron Hydrochloride Oral Spray (DOMI-UP) Paracetamol 1000mg Programmed Release Tablet (PA-12) Micronized Progesterone Vaginal Spray (PR
Slide 15: Innovations - Lincoln Pharma
Innovations - Lincoln Pharma Q1 FY2022 Earnings Presentation 15
Slide 16: New Launches – Domestic Market
New Launches – Domestic Market Q1 FY2022 Earnings Presentation 16
Slide 17: New Launches – International Market
New Launches – International Market Q1 FY2022 Earnings Presentation 17
Slide 18: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Gyneacological Sterile Ophthalmic Dermatologist Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-malarial Anti-viral/ Anti- Otology / Anti-
Slide 19: Best in Class Facilities
Best in Class Facilities Certifications: EU-GMP, WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption; 1MW Solar Roof installed Dosage Forms Produced at Unit 1 Dosage Forms Produce
Slide 20: Financial Highlights
Financial Highlights Revenue EBITDA 93 424 67 66 386 53 47 360 361 366 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 PAT Net Worth 376 62 313.1 51 269.3 49 224.5 35 192.6 28 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 Q1 FY2022 Ea
Slide 21: Profitability Ratios
Profitability Ratios EBITDA Margin PAT Margin 18% 21% 13.4% 14.6% 17% 13.2% 15% 13% 9.7% 7.8% FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 ROCE RONW 22.0% 22.1% 18.3% 21.0% 20.5% 17.0% 16.3% 17.5% 15.0% 12.7% FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018
Slide 22: Shareholding Information
Shareholding Information June 2021 March 2021 Investor Category No. of No. of Shares % Holding No. of No. of Shares % Holding Shareholders Held Shareholders Held Promoter Group 30 75,56,339 37.78% 30 74,51,904 37.26% Public Holding 26,390 1,24,43,661 62.22% 21,385 1,25,48,096 62.74% Total 26,420 2,0
Slide 23: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h, Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060, Gujarat, INDIA Phone: +91-79-41078000 Fax: +91-79-41078062 E-mail: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit A. Shah Gopal Modi CFO, Lincoln Pharmaceuticals Lt
Lincoln Pharmaceuticals — Q1 FY2022 Earnings Presentation on 6ix